TIDMBIOM
RNS Number : 0415M
Biome Technologies PLC
12 September 2019
12 September 2019
Biome Technologies plc
("Biome", "the Company" or "the Group")
Interim Results
Biome Technologies plc announces its unaudited Interim Results
for the six months ended 30 June 2019.
Highlights
-- The Group generated revenues of GBP3.6m and gross profit of GBP1.7m
-- The Biome bioplastics division is continuing towards becoming
the principal revenue generator for the Group
-- Biome bioplastics revenues were generated from both existing
products as well as the early phase of commercialisation of three
new products
-- Stanelco RF division trading in line with normalised levels of fibre optic furnace demand
Paul Mines, Chief Executive Officer said:
"The first half of 2019 has seen substantial progress in the
commercialisation of three new products in the Bioplastics division
with initial revenues in the latter part of the period. Against
this backdrop it is anticipated that the Group will evolve with the
Bioplastics division becoming the principal revenue generator in
coming periods."
- Ends -
For further information please contact: Biome Technologies plc
Paul Mines, Chief Executive Officer
Declan Brown, Group Finance Director
www.biometechnologiesplc.com Tel: +44 (0) 2380 867
100
Allenby Capital
David Hart/Alex Brearley (Nominated Adviser)
Kelly Gardiner (Broker)
www.allenbycapital.com Tel: +44 (0) 20 3328
5656
About Biome
Biome Technologies plc (Ticker:BIOM) is an AIM listed,
growth-orientated, commercially driven technology group. Our
strategy is founded on building market-leading positions based on
patented technology and serving international customers in valuable
market sectors. We have chosen to do this by developing products in
application areas where the value-added pricing can be justified
and that are not reliant on government legislation. These products
are driven by customer requirements and are compatible with
existing manufacturing processes. They are market rather than
technology-led.
The Group comprises two divisions, Biome Bioplastics Limited and
Stanelco RF Technologies Limited. Biome Bioplastics is a leading
developer of highly-functional, bio-based and biodegradable
plastics. The company's mission is to produce bioplastics that
challenge the dominance of oil-based polymers. Stanelco RF
Technologies designs, builds and services advanced radio frequency
(RF) systems. Dielectric and induction heating products are at the
core of a product offering that ranges from portable sealing
devices to large furnaces for the fibre optics markets.
In 2018, the Board adopted the following three high level KPIs
for the next three years to continue its ambitious momentum:
-- Compound revenue growth of 25% per annum across the Group and
40% compound revenue growth in the Bioplastics division
-- Diversify the Group's turnover by product and market to
ensure that no one product or end customer contributes more than
15% of revenues by 2020
-- Increase investment in the Group's next generation of
products by spending significantly more per annum on average than
the GBP0.3m per annum average spend over the previous strategic
objective cycle
www.biometechnologiesplc.com
www.biomebioplastics.com and www.thinkbioplastic.com
www.stanelcorftechnologies.com
#ThinkBioplastic is our digital educational platform, launched
in October 2018 in response to the emerging global plastic
conversation. It speaks to a wide audience, highlighting
bioplastics as a leading solution among several to reduce the
negative impact of plastic manufacture and disposal. Following the
much acclaimed first series of short videos the second series was
recently released.
Chairman's Statement
The Group's Bioplastics division continues its strong growth
path towards becoming the principal revenue generator for the
Group. In that context, the Bioplastics division delivered a more
than 50% increase in revenues in the first half of the year. Group
revenues were GBP3.6m 2019 (H1 2018: GBP4.4m) which reflected a
more normal level of revenue at the Stanelco RF Technologies
division after the exceptional level of sales in 2018.
Gross profit was GBP1.7m (H1 2018: GBP2.3m) impacted by the
effect of the revenues highlighted above. The overall gross margin
for the Group was 48% (H1 2018: gross margin 53%) reflecting the
increased weighting of sales towards the Bioplastics division.
The Group recorded a small loss before interest, depreciation,
amortisation and share option charges for the six months to 30 June
2019 of GBP0.2m (H1 2018: GBP0.5m profit). The loss after taxation
was GBP0.5m (H1 2018: GBP0.2m profit), which equates to a loss per
share of 20 pence on a basic basis and diluted basis (H1 2018:
profit per share of 9 pence on a basic and diluted basis).
The Group's cash position as at 30 June 2019 was GBP1.7m (31
December 2018: GBP2.6m) reflecting the increase in working capital
requirements in line with activity.
Biome Bioplastics Division
Revenues in the Bioplastics division for the first half of 2019
were GBP1.4m (H1 2018: GBP0.9m) with this turnover reflecting
increases in existing products as well as the early phase of
commercialisation of three new products.
The operating loss for the period was GBP0.3m (2018: operating
loss of GBP0.3m).
We gained some initial revenues for the following three products
with customers in the USA in the first half of the year:
-- a new material for single serve pods in the sports nutrition market
-- a new material for use in the compostable disposable cutlery market
-- plastic film products for a new customer
It is anticipated that revenues from these products will
increase over the coming quarters as they scale up in line with
customer demands.
The Bioplastics team is now also working on a strong product
development pipeline of other opportunities with a variety of
existing and new customers.
To further these opportunities, a number of new commercial and
technical team members have been recruited into the business in the
last 12 months and they are all now making significant
contributions alongside their more experienced colleagues. Sally
Morley, until recently the Commercial Director of the division, has
recently been appointed Managing Director. This strengthening of
the team's leadership has enabled other organisational changes as
the business adjusts to heightened levels of activity in both
manufacturing and development.
The division has continued with its mid-term strategy to develop
a new range of lignocellulose-derived bioplastics, with the aim of
generating bio-based and biodegradable plastic products with
increased performance that can be produced at a cost more
comparable to traditional plastics made from petro-chemicals. This
work is supported by a number of government grants. During the
first half of the year, development work commenced on the scale up
of one of the new monomers in conjunction with Nottingham
University. Further updates on the progress of these projects will
be made as they evolve.
Stanelco RF Technologies Division
Revenues in the RF Technologies division were GBP2.2m (H1 2018:
GBP3.5m) reflecting a return to the more normalised levels of fibre
optic furnace demand from the previously reported exceptional
demand recorded in 2018. As a result of this, operating profit
recorded in the first half of the year was GBP0.6m (H1 2018:
GBP1.3m).
The division signed a GBP1.3m contract for the supply of a
number of fibre optic furnaces in the second half of 2019 and it is
against this backdrop that the Board continues to expect full year
revenues for this division to be in line with those of 2017.
Outlook
The Bioplastics division has made substantial progress in its
aim of commercialising new products within the last six months and
additional revenue growth is expected in forthcoming quarters. In
line with its previous expectations, the Board anticipates that the
Bioplastics division will maintain a gradual but sustained increase
in revenues in 2019 and will eclipse the RF Technologies division
as the main revenue generator for the Group in a year or so.
The commercial opportunities in bioplastics that we are sourcing
are growing in scale and improving in quality. The Board will
continue to use all available means possible to take advantage of
this change in market dynamic for the benefit of shareholders.
John Standen
Chairman
CONSOLIDATED STATEMENT
OF COMPREHENSIVE INCOME
For the period ended 30 June 2019
Total Total
for for
6 Months 6 Months Total Year
Ended Ended Ended
30 June 30 June 31 December
2019 2018 2018
Unaudited Unaudited Audited
Note GBP'000 GBP'000 GBP'000
----------------------------------------- ----- ---------- ---------- ------------
5a -
REVENUE 5c 3,605 4,391 8,850
Cost of sales (1,890) (2,068) (4,042)
GROSS PROFIT 1,715 2,323 4,808
Administrative expenses (2,210) (2,117) (4,745)
5a -
PROFIT/(LOSS) FROM OPERATIONS 5c (495) 206 63
Profit/(Loss) from operations before
share options charges (424) 311 281
Share options charges (71) (105) (218)
Investment revenue 3 2 4
Foreign exchange gain 8 8 17
PROFIT/(LOSS) BEFORE TAXATION (484) 216 84
Taxation 6 - - 59
TOTAL COMPREHENSIVE (LOSS)/INCOME FOR
THE PERIOD ATTRIBUTABLE TO THE EQUITY
HOLDERS OF THE PARENT (484) 216 143
========== ========== ============
Basic earnings/(loss) per share - pence 7 (20) 9 6
Diluted earnings/(loss) per share -
pence 7 (20) 9 5
CONSOLIDATED STATEMENT
OF FINANCIAL POSITION
As at 30 June 2019
At At At
30 June 30 June 31 December
2019 2018 2018
Unaudited Unaudited Audited
Note GBP'000 GBP'000 GBP'000
--------------------------------------- ----- ---------- ---------- ------------
NON-CURRENT ASSETS
Other intangible assets 8 931 891 918
Property, plant and equipment 9 179 161 185
---------- ---------- ------------
1,110 1,052 1,103
---------- ---------- ------------
CURRENT ASSETS
Inventories 10 548 861 955
Trade and other receivables 11 1,232 1,555 873
Cash and cash equivalents 1,731 2,307 2,614
---------- ---------- ------------
3,511 4,723 4,442
---------- ---------- ------------
TOTAL ASSETS 4,621 5,775 5,545
========== ========== ============
CURRENT LIABILITIES
Trade and other payables 12 1,281 2,063 1,792
1,281 2,063 1,792
---------- ---------- ------------
TOTAL LIABILITIES 1,281 2,063 1,792
========== ========== ============
NET ASSETS 3,340 3,712 3,753
========== ========== ============
EQUITY
Share capital 118 118 118
Share premium account 805 793 805
Capital redemption reserve 4 4 4
Share options reserve 314 214 316
Translation reserve (85) (85) (85)
Retained profits 2,184 2,668 2,595
EQUITY ATTRIBUTABLE TO EQUITY HOLDERS
OF THE PARENT AND TOTAL EQUITY 3,340 3,712 3,753
========== ========== ============
The interim statements were approved by the Board on 11
September 2019.
Signed on behalf of the Board of Directors
Paul R Mines (Chief Executive)
Declan L Brown (Group Finance Director)
11 September 2019
CONSOLIDATED STATEMENT
OF CHANGES IN EQUITY
As at 30 June 2019
Share Capital Share
Share premium redemption options Translation Retained TOTAL
capital account reserve reserve reserve earnings EQUITY
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Unaudited
Balance at 1 January
2019 118 805 4 316 (85) 2,595 2,595
========= ========= ============ ========= ============ ========== ========
Share options issued
in share based payments - - - 71 - - 71
Cancellation of
time expired share
options - - - (73) - 73 -
--------- --------- ------------ --------- ------------ ---------- --------
Transactions with
owners - - - (2) - 73 71
--------- --------- ------------ --------- ------------ ---------- --------
Loss for the period - - - - - (484) (484)
Total comprehensive
income for the period - - - - - (484) (484)
--------- --------- ------------ --------- ------------ ---------- --------
Balance 30 June
2019 118 805 4 314 (85) 2,184 3,340
========= ========= ============ ========= ============ ========== ========
Unaudited
Balance at 1 January
2018 117 740 4 219 (85) 2,342 3,337
========= ========= ============ ========= ============ ========== ========
Issue of share capital 1 53 - - - - 54
Share options issued
in share based payments - - - 105 - - 105
Cancellation of
time expired share
options - - - (110) - 110 -
Transactions with
owners 1 53 - (5) - 110 159
--------- --------- ------------ --------- ------------ ---------- --------
Profit for the period - - - - - 216 216
Total comprehensive
income for the period - - - - - 216 216
--------- --------- ------------ --------- ------------ ---------- --------
Balance 30 June
2018 118 793 4 214 (85) 2,668 3,712
========= ========= ============ ========= ============ ========== ========
Share Capital Share
Share premium redemption options Translation Retained TOTAL
capital account reserve reserve reserves earnings EQUITY
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
Audited
Balance at 1 January
2018 117 740 4 219 (85) 2,342 3,337
========= ========= ============ ========= ============ ========== ========
Issue of share capital 1 54 - - - - 55
Share options issued
in share based payments - - - 218 - - 218
Exercise of share
options - 11 - (11) - - -
Cancellation of
time expired share
options - - - (110) - 110 -
Transactions with
owners 1 65 - 97 - 110 273
--------- --------- ------------ --------- ------------ ---------- --------
Profit for the year - - - - - 143 143
Total comprehensive
income for the year - - - - - 143 143
--------- --------- ------------ --------- ------------ ---------- --------
Balance 31 December
2018 118 805 4 316 (85) 2,595 3,753
========= ========= ============ ========= ============ ========== ========
CONSOLIDATED STATEMENT
OF CASH FLOWS
For the period ended 30 June 2019
6 Months 6 Months Year
Ended Ended ended
30 June 30 June 31 December
2019 2018 2018
Unaudited Unaudited Audited
GBP'000 GBP'000 GBP'000
------------------------------------------- ---------- ---------- ------------
(Loss)/profit from operations (495) 206 63
Adjustment for:
Amortisation and impairment of intangible
assets 148 145 290
Depreciation of property, plant and
equipment 29 29 57
Share based payments 71 105 218
Foreign exchange 5 8 16
---------- ---------- ------------
Operating cash flows before movement
of working capital (242) 493 644
Decrease/(increase) in inventories 407 (63) (158)
(Increase)/decrease in receivables (414) (220) 521
(Decrease)/increase in payables (512) (8) (277)
---------- ---------- ------------
Cash utilised in operations (761) 202 730
Corporation tax (paid)/received 59 - -
---------- ---------- ------------
Net cash inflow/(outflow) from operating
activities (702) 202 730
---------- ---------- ------------
Cash flows from investing activities
Interest received 3 2 4
Investment in intangible assets (161) (122) (293)
Purchase of property, plant and equipment (23) (68) (120)
---------- ---------- ------------
Net cash used in investing activities (181) (188) (409)
---------- ---------- ------------
Net (decrease)/increase in cash and
cash equivalents (883) 14 321
Cash and cash equivalents at beginning
of period 2,614 2,293 2,293
---------- ---------- ------------
Cash and cash equivalents at end
of period 1,731 2,307 2,614
========== ========== ============
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS
For the period ended 30 June 2019
1. CORPORATE INFORMATION
The financial information for the year ended 31 December 2018
set out in this interim report does not constitute statutory
accounts as defined in Section 434 of the Companies Act 2006. The
Group's statutory financial statements for the year ended 31
December 2018 have been filed with the Registrar of Companies. The
auditor's report on those financial statements was unqualified and
did not contain statements under Section 498 of the Companies Act
2006. The interim results are unaudited. Biome Technologies plc is
a public limited company incorporated and domiciled in England
& Wales. The Company's ordinary shares are publicly traded on
the AIM market of the London Stock Exchange.
2. BASIS OF PREPARATION
These interim consolidated financial statements (the interim
financial statements) are for the six months ended 30 June 2019.
They have been prepared in accordance with IFRSs as adopted by the
European Union and IAS 34 Interim Financial Reporting. They do not
include all of the information required for full annual financial
statements, and should be read in conjunction with the consolidated
financial statements of the Group for the year ended 31 December
2018.
These interim financial statements have been prepared under the
historical cost convention.
These interim financial statements have been prepared in
accordance with the accounting policies adopted in the last annual
financial statements for the year to 31 December 2018 except for
the adoption of IFRS 16 as described below.
On 1 January 2019, the Group adopted IFRS 16 'Leases' which
supersedes IAS 17 'Leases'. The Group has adopted the 'Modified
retrospective application' which means there is no restatement of
the comparative period but there is an opening adjustment to
retained earnings as at 1 January 2019 to account for any lease
costs taken in 2018 that need to be reclassified to 2019. Following
a review of all leases, it has been determined that no opening
adjustments with respect to the adoption of IFRS 16 are required.
This is due to the main lease for the property having less than one
year to expiry.
The accounting policies have been applied consistently
throughout the Group for the purposes of preparation of the interim
financial statements.
3. BASIS OF CONSOLIDATION
The Group interim financial statements consolidate the results
of the Company and all of its subsidiary undertakings drawn up to
30 June 2019. At 30 June 2019, the subsidiary undertakings were
Biome Bioplastics Limited, Stanelco RF Technologies Limited,
Aquasol Limited and InGel Technologies Limited.
4. GOING CONCERN
The directors have reviewed forecasts and budgets for the coming
12 months, which have been drawn up with appropriate regard for the
current macroeconomic environment and the particular circumstances
in which the Group operates. As a result of this process, the
directors are satisfied that the Group has sufficient resources to
continue in operational existence for at least one year from the
date of approval of the interim report.
5a. SEGMENTAL INFORMATION FOR 6 MONTHSED 30 JUNE 2019
RF Central
Bioplastics Technologies Costs Total
6 Months 6 Months 6 Months 6 Months
Ended ended ended Ended
30 June 30 June 30 June 30 June
2019 2019 2019 2019
GBP'000 GBP'000 GBP'000 GBP'000
Unaudited
Revenue from external customers 1,442 2,163 - 3,605
(LOSS)/PROFIT FROM OPERATIONS (344) 584 (735) (495)
Investment revenue 3
Foreign exchange gain 8
LOSS ATTRIBUTABLE TO EQUITY
SHAREHOLDERS (483)
=========
TOTAL ASSETS 2,088 717 1,816 4,621
================================= ============ ============== ========= =========
5b. SEGMENTAL INFORMATION FOR 6 MONTHSED 30 JUNE 2018
RF Central
Bioplastics Technologies Costs Total
6 Months 6 Months 6 Months 6 Months
ended Ended ended Ended
30 June 30 June 30 June 30 June
2018 2018 2018 2018
GBP'000 GBP'000 GBP'000 GBP'000
Unaudited
Revenue from external customers 932 3,459 - 4,391
(LOSS)/PROFIT FROM OPERATIONS (345) 1,279 (728) 206
Investment revenue 2
Foreign exchange gain 8
PROFIT ATTRIBUTABLE TO EQUITY
SHAREHOLDERS 216
=========
TOTAL ASSETS 1,940 1,931 1,904 5,775
================================= ============ ============== ========= =========
5c. SEGMENTAL INFORMATION FOR YEARED 31 DECEMBER 2018
RF Central
Bioplastics Technologies Costs Total
Year Year Year Year
ended ended ended ended
31 31 31
December December 31 December December
2018 2018 2018 2018
GBP'000 GBP'000 GBP'000 GBP'000
Audited
Revenue from external customers 1,890 6,960 - 8,850
(LOSS)/PROFIT FROM OPERATIONS (792) 2,601 (1,746) 63
Investment revenue 4
Foreign exchange gain 17
PROFIT BEFORE TAXATION FROM
OPERATIONS 84
Taxation 59
PROFIT ATTRIBUTABLE TO EQUITY
SHAREHOLDERS 143
==========
TOTAL ASSETS 1,846 945 2,754 5,545
================================= ============ ============== ============ ==========
6. TAXATION
The Group's policy is to recognise tax credits resulting from
tax research and development claims on a cash received basis. The
claim in respect of the year ended 31 December 2018 has not yet
been settled and there is therefore no tax credit recognised in the
period under review.
7. EARNINGS PER SHARE
The calculation of basic earnings per share is based on the loss
attributable to the equity holders of the parent for the six months
of GBP484,000 (2018: profit of GBP216,000) and a weighted average
of 2,365,188 (2018: 2,352,465) ordinary shares in issue. The
calculation uses the same weighted average number of shares under
the basic and diluted basis in the current period due to a loss
being made.
Diluted earnings per share for the six months ended 30 June 2018
were based on a weighted average of 2,485,111 ordinary shares (31
December 2018: 2,782,194 ordinary shares) which accounts for all
share options which are in the money, regardless of whether they
have yet vested.
8. OTHER INTANGIBLE ASSETS
Other intangible assets increased in the period as a result of
the capitalisation of product development costs of GBP161,000
exceeding the amortisation charge of GBP148,000.
9. PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment decreased in the reporting period
as a result of the depreciation charge for the period of GBP29,000
exceeding the purchase of property, plant and equipment of
GBP23,000.
10. INVENTORIES
The decrease in inventories during the reporting period reflects
the decrease in equipment orders under construction within the
Stanelco RF division.
11. TRADE AND OTHER RECEIVABLES
Trade and other receivables have increased during in the
reporting period mainly due to the increases in trade debtors
within both the Biome Bioplastics and Stanelco RF divisions and
reflects the timing of invoicing and shipments around the period
end.
12. TRADE AND OTHER PAYABLES
The decrease in trade and other payables during the reporting
period primarily reflects the decrease in activity levels, and
equipment sale deposits, within the Stanelco RF division.
13. RISKS AND UNCERTAINTIES
The principal risks and uncertainties affecting the business
activities of the Group are detailed in the Strategic Report which
can be found on pages 6-12 of the Annual Report and Financial
Statements for the year ended 31 December 2018 ("the Annual
Report"). A copy of the Annual Report and Financial Statements is
available on the Company's website at
www.biometechnologiesplc.com
The directors consider that the risks affecting the business
remain the same as in the Annual Report. In summary, these risks
include:
-- changes in the regulatory environments in which the Group operates
-- fluctuations in exchange rates
-- volatility in raw material prices and supply
-- breach of intellectual property rights
-- competitors developing more attractive products
-- failure to commercialise products
-- reliance on a small number of customers for certain products
-- financial risks including exchange rate risk, liquidity risk,
interest rate risk and credit risk.
Further details of how these risks impact the business and how
the directors attempt to mitigate
the risks can be found in the Annual Report.
Copies of this interim report will be shortly available on the
Company's website at www.biometechnologiesplc.com.
INDEPENDENT REVIEW REPORT FOR BIOME TECHNOLOGIES PLC
Introduction
We have reviewed the condensed set of financial statements in
the half-yearly financial report of Biome Technologies Plc (the
'company') for the six months ended 30 June 2019 which comprises
the consolidated statement of comprehensive income, consolidated
statement of financial position, consolidated statement of changes
in equity, consolidated statement of cash flows and the related
notes. We have read the other information contained in the half
yearly financial report which comprises only the Chairman's
Statement and considered whether it contains any apparent
misstatements or material inconsistencies with the information in
the condensed set of financial statements.
Directors' responsibilities
The half-yearly financial report is the responsibility of, and
has been approved by, the directors. As disclosed in note 2, the
annual financial statements of the group are prepared in accordance
with International Financial Reporting Standards as adopted by the
European Union. The condensed set of financial statements included
in this half-yearly financial report has been prepared in
accordance with International Accounting Standard 34, 'Interim
Financial Reporting', as adopted by the European Union.
Our responsibility
Our responsibility is to express a conclusion to the company on
the condensed set of financial statements in the half-yearly
financial report based on our review.
Scope of review
We conducted our review in accordance with International
Standard on Review Engagements (UK and Ireland) 2410, 'Review of
Interim Financial Information Performed by the Independent Auditor
of the Entity'. A review of interim financial information consists
of making enquiries, primarily of persons responsible for financial
and accounting matters, and applying analytical and other review
procedures. A review is substantially less in scope than an audit
conducted in accordance with International Standards on Auditing
(UK) and consequently does not enable us to obtain assurance that
we would become aware of all significant matters that might be
identified in an audit. Accordingly, we do not express an audit
opinion.
Conclusion
Based on our review, nothing has come to our attention that
causes us to believe that the condensed set of financial statements
in the half-yearly financial report for the six months ended 30
June 2019 is not prepared, in all material respects, in accordance
with International Accounting Standard 34, 'Interim Financial
Reporting', as adopted by the European Union.
Use of our report
This report is made solely to the company as a body, in
accordance with International Standard on Review Engagements (UK
and Ireland) 2410, 'Review of Interim Financial Information
performed by the Independent Auditor of the Entity'. Our review
work has been undertaken so that we might state to the company
those matters we are required to state therein in an independent
review report and for no other purpose. To the fullest extent
permitted by law, we do not accept or assume responsibility to
anyone other than the company as a body, for our review work, for
this report, or for the conclusion we have formed.
GRANT THORNTON UK LLP
STATUTORY AUDITOR
CHARTERED ACCOUNTANTS
SOUTHAMPTON
11 September 2019
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IR SFAFAFFUSESU
(END) Dow Jones Newswires
September 12, 2019 02:00 ET (06:00 GMT)
Biome Technologies (LSE:BIOM)
Historical Stock Chart
From Apr 2024 to May 2024
Biome Technologies (LSE:BIOM)
Historical Stock Chart
From May 2023 to May 2024